Autotransfusion System Market Size
Global Autotransfusion System Market reached US$ 321.4 million in 2022 and is expected to reach US$ 482.6 million by 2030 growing with a CAGR of 5.3% during the forecast period 2024-2031.
The autotransfusion system process blood collected from a surgical site to produce washed red blood cells for return to a patient later. This is achieved with only one kit and one program. In these autotransfusion system blood is stored at room temperature for a short time, so deterioration of clotting factors and cells is minimal. Advantages of these systems include a lower cost than for predeposit transfusion and minimal wastage, as most or all blood is reinfused.
Furthermore, the huge number of surgeries and lack of donors drive the market size. Due to the product launches and FDA approvals, the market is seeing an increase in the North American region with significant players like LivaNova, Atrium Medical Corporation, Fresenius Kabi, Armstrong Medical, Beijing ZKSK Technolgy, Medtronic, and others actively operating in the market.
Market Scope
Metrics | Details |
CAGR | 5.3% |
Size Available for Years | 2021-2030 |
Forecast Period | 2024-2031 |
Data Availability | Value (US$) |
Segments Covered | Product Type, Techniques, Application, End User, and Region |
Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
Fastest Growing Region | Asia-Pacific |
Largest Region | North America |
Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
To Know More Insights - Download Sample
Market Dynamics
Rising Number of Surgeries with Maximum Blood Loss
- The rising number of surgeries with maximum blood loss is driving the market growth. The number of complex surgeries, including cardiac, orthopedic, trauma, and big abdominal surgery, is increasing with the increasing incidence of chronic diseases. These surgeries frequently result in significant blood loss, making it critical to have systems in place that can recapture and reinfuse the patient's blood to keep them stable during the surgery. As the number of high-risk procedures increases, the demand for autotransfusion devices.
- For instance, according to the report by the National Institute of Health in 2024, a total of 54,418 cardiac surgeries were conducted during 20 years, with isolated CABG being the most frequently performed surgery. The number of these surgeries is expected to rise with the growing number of individuals suffering from various conditions.
- According to the National Institute of Health in 2023, the number of cardiac procedures.
High Cost
- The high cost of autotransfusion systems is a significant restraint in the industry, particularly for smaller hospitals and healthcare facilities in underdeveloped countries. The initial investment for these advanced devices can be prohibitive, limiting access to essential devices and systems. The price for autotransfusion systems varies from company to company. For instance, Medtronic USA Cell Saver autoLog Autotransfusion Systems - Cell Saver autoLog One Source Autotransfusion System Pack with 120 micron Filter - ATLS21 cost is around $380.99.
- This expensive barrier inhibits their capacity to get and use such technologies, which are required for good blood management during procedures. Beyond the initial investment, continuing maintenance expenses might be significant, discouraging prospective customers from investing in autotransfusion systems. Many developing countries suffer economic constraints that restrict them from investing in innovative medical technology. As a result, autotransfusion systems have a lower market penetration in these regions, since healthcare professionals prioritize more immediate needs over costly equipment.
Market Segment Analysis
The global autotransfusion system market is segmented based on product type, technique, application, and end user.
The Neurology Segment is Expected to Hold a Position in the Market Over the Forecast Period
Neurology accounted for the significant market share, accounting for approximately 24.3% of the autotransfusion system market in 2022. The prevalence of neurological surgeries is driving the autotransfusion market. For instance, according to the National Institutes of Health(NIH), an estimated 22.6 Billion patients suffer from neurological disorders or injuries that warrant the expertise of a neurosurgeon, of whom 13.8 Billion require surgery every year.
The incidence of neurological disorders is paving the way for the conduction of neurological surgeries. Thus, these factors are influencing the use of autotransfusion systems. Hence, these factors drive segment growth.
Source: DataM Intelligence Analysis (2023)
Market Geographical Share
North America Remains the Dominant Region in the Global Autotransfusion System Market for Around 39.9% of Market Share in 2022
The strategies of the key players help to boost the growth of the region. For instance, on March 2, 2023, Fresenius Kabi, a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on the next-generation software for the Cell Saver Elite+ Autotransfusion System, with complete market release available.
Additionally, on April 24, 2023, San Diego Blood Bank launched Innovative Precision Blood Expansion. Precision Blood typing matches blood recipients with donors of 30+ blood groups using 300 antigen markers, which can reduce blood transfusion reactions – a breakthrough that transforms the standard of care for patients. Hence, product approvals and the launches of the products help to drive the region.
Source: DataM Intelligence Analysis (2023)
Companies
The major global players in the market include BD, Fresenius Kabi, Zimmer, Armstrong Medical, Beijing ZKSK Technolgy, Haemonetics, LivaNova, Terumo BCT, Atrium Medical Corporation, Medtronic among others.
COVID-19 Impact Analysis
Russia-Ukraine War Impact Analysis
The Russia-Ukraine is estimated to have a minimal impact on the global autotransfusion system market owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials, test product types, and devices is anticipated to have little influence over the global autotransfusion system market in the forecast period.
By Product type
- Intraoperative Autotransfusion Systems
- Postoperative Autotransfusion Systems
- Dual-Mode Autotransfusion Systems
- Autotransfusion Accessories
By Technique
- Predeposit autologous donation (PAD)
- Acute normovolaemic haemodilution (ANH)
- Perioperative cell salvage (PCS)
By Application
- Orthopedic
- Neurology
- Cardiology
- Others
By End User
- Hospitals
- Specialty Clinics
- Others
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- Germany
- The U.K.
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
Key Developments
- On October 29, 2021, Morgan Stanley Infrastructure Partners Completes Investment in Specialty Care. The specialty care operates the leading network of outsourced clinical services to hospital operating rooms in the U.S. With 1,200+ client hospitals in 46 U.S. states, it is the leading provider of cardiovascular perfusion, extracorporeal membrane oxygenation (“ECMO”), intraoperative neuromonitoring (“IONM”), and autologous perfusion services (“ATS”).
- On March 02, 2023, Haemonetics announced that it was approved by FDA 510(k) clearance for next-generation software for the Cell Saver Elite+ autotransfusion system. According to Haemonetics, the system’s new software offers over 50 automation enhancements. These include complete user control with a “manual mode” option, expanded wash volumes, and enhanced emergency options.
- In September 2022, i-SEP received CE-marking and initiated marketing of its autotransfusion medical device, same by i-SEP. It is one of the intraoperative autotransfusion technology capable of preserving platelets in addition to the patient's red blood cells.
Why Purchase the Report?
- To visualize the global autotransfusion system market segmentation based on product type, application, techniques, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of autotransfusion system market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available in Excel consisting of key product types of all the major players.
The global autotransfusion system market report would provide approximately 53 tables, 54 figures, and 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies